Abstract
Varenicline is a promising agent with demonstrated efficacy in the promotion of smoking cessation. However, from the time of initial trials, it has been associated with significant psychiatric adverse effects. We describe a case where mixed mood and psychotic disturbance developed in an individual with a history of depression and a family history of bipolar disorder. Based on this case, we hypothesize a possible mechanism of action for these adverse effects and preventive measures that could be undertaken in its effective use.
MeSH terms
-
Antipsychotic Agents / therapeutic use
-
Aripiprazole
-
Benzazepines / adverse effects*
-
Benzazepines / therapeutic use
-
Bipolar Disorder / chemically induced*
-
Bipolar Disorder / diagnosis
-
Bipolar Disorder / genetics
-
Bipolar Disorder / psychology
-
Depressive Disorder / diagnosis
-
Depressive Disorder / genetics*
-
Depressive Disorder / psychology
-
Depressive Disorder / therapy
-
Female
-
Genetic Predisposition to Disease / genetics
-
Humans
-
Middle Aged
-
Piperazines / therapeutic use
-
Psychoses, Substance-Induced / diagnosis
-
Psychoses, Substance-Induced / drug therapy
-
Psychoses, Substance-Induced / genetics*
-
Psychoses, Substance-Induced / psychology
-
Psychotherapy
-
Quinolones / therapeutic use
-
Quinoxalines / adverse effects*
-
Quinoxalines / therapeutic use
-
Smoking Cessation*
-
Stress, Psychological / complications
-
Varenicline
Substances
-
Antipsychotic Agents
-
Benzazepines
-
Piperazines
-
Quinolones
-
Quinoxalines
-
Aripiprazole
-
Varenicline